{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:09:45Z","timestamp":1790334585731,"version":"4.1.0"},"reference-count":79,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Syst. Biol."],"abstract":"<jats:p>\n                    Globally, Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prominent leading cause of CLD, which is intricately linked with obesity, T2D, and metabolic syndrome. Recent insights in pathophysiologically of MASLD have shifted from the traditional \u201ctwo-hit\u201d model to a \u201cmultiple-hit\u201d paradigm, demonstrating the importance of understanding the gut-liver axis and gut dysbiosis as central drivers of disease progression. Hence, this narrative review explores the mechanistic pathways through which an altered gut microbiome contributes to MASLD, by specifically emphasizing intestinal barrier disruption, endotoxemia, altered bile acid metabolism, and SCFA imbalance. These dysregulations trigger oxidative stress, leading to systemic inflammation and insulin resistance, propelling simple steatosis toward steatohepatitis and fibrosis at last. Furthermore, we also highlighted the diagnostic utility of microbial signatures and multi-omics approaches in identifying disease-specific microbial shifts, such as the depletion of beneficial SCFA-producing bacteria like\n                    <jats:italic>Faecalibacterium<\/jats:italic>\n                    and\n                    <jats:italic>Akkermansia<\/jats:italic>\n                    . Eventually, to address the growing hepatic-associated health burden, microbiome-targeted therapeutics can emerge as one of the promising contributors. In this review, we synthesise and demonstrate the current and prospective interventions, including dietary modifications, biotics (probiotics, prebiotics, synbiotics), and FMT. Additionally, we also show the transition of care toward precision microbiome therapies utilizing engineered bacteria, bacteriophages, and AI-guided patient stratification. While current microbiome-centric treatments demonstrate promise in modulating hepatic inflammation and restoring mucosal integrity, their clinical translation remains hindered by patient heterogeneity and a lack of standardized protocols. Ultimately, managing MASLD effectively will require moving beyond broad ecosystem resets toward highly tailored, multi-omics-driven precision medicine to accurately target individualized microbial deficits.\n                  <\/jats:p>","DOI":"10.3389\/fsysb.2026.1937809","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:34:25Z","timestamp":1790332465000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting gut dysbiosis: a new frontier in MASLD management"],"prefix":"10.3389","volume":"6","author":[{"given":"Shweta","family":"Sharma","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University","place":["Vadodara, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Pachauri","sequence":"additional","affiliation":[{"name":"Preventive Health and Clinical Services, Deepak Foundation","place":["Vadodara, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshal","family":"Nagar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University","place":["Vadodara, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishwa","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University","place":["Vadodara, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Parul Institute of Pharmacy, Faculty of Pharmacy, Parul University","place":["Vadodara, Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/livers5010011","article-title":"Gut microbiota and metabolic dysfunction-associated steatotic liver disease (MASLD): emerging pathogenic mechanisms and therapeutic implications","volume":"5","author":"Abdelhameed","year":"2025","journal-title":"Livers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"9715","DOI":"10.3390\/ijms25179715","article-title":"Insights into gut dysbiosis: inflammatory diseases, obesity, and restoration approaches","volume":"25","author":"Acevedo-Rom\u00e1n","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/livers5020017","article-title":"The intestinal thread of fate: how the microbiota shapes the story of liver disease","volume":"5","author":"Acierno","year":"2025","journal-title":"Livers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1695329","DOI":"10.3389\/fmedt.2025.1695329","article-title":"Microbiome-based therapeutics for metabolic disorders: harnessing microbial intrusions for treatment","volume":"7","author":"Ahmed","year":"2025","journal-title":"Front. Med. Technol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.3390\/antibiotics12050868","article-title":"Future modulation of gut microbiota: from eubiotics to FMT, engineered bacteria, and phage therapy","volume":"12","author":"Airola","year":"2023","journal-title":"Antibiotics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3746\/pnf.2020.25.2.113","article-title":"The influence of the gut microbiome on obesity in adults and the role of probiotics, prebiotics, and synbiotics for weight loss","volume":"25","author":"Aoun","year":"2020","journal-title":"Prev. Nutrition Food Science"},{"key":"B7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12967-025-07428-9","article-title":"Dietary interventions and the gut microbiota: a systematic literature review of 80 controlled clinical trials","volume":"24","author":"Aslam","year":"2026","journal-title":"J. Transl. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1637071","DOI":"10.3389\/fnut.2025.1637071","article-title":"\u201cTrust your gut\u201d: exploring the connection between gut microbiome dysbiosis and the advancement of metabolic associated steatosis liver disease (masld)\/metabolic associated steatohepatitis (MASH): a systematic review of animal and human studies","volume":"12","author":"Bahitham","year":"2025","journal-title":"Front. Nutr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2331460","DOI":"10.1080\/19490976.2024.2331460","article-title":"Breaking the barriers: the role of gut homeostasis in metabolic-associated steatotic liver disease (MASLD)","volume":"16","author":"Bened\u00e9-Ubieto","year":"2024","journal-title":"Gut Microbes"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e100204","DOI":"10.1136\/egastro-2025-100204","article-title":"Gut dysbiosis is linked to severe steatosis and enhances its diagnostic performance in MASLD","volume":"3","author":"Borges-Canha","year":"2025","journal-title":"Egastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s41579-023-00888-0","article-title":"Roles of the gut microbiome in weight management","volume":"21","author":"Carmody","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1575770","DOI":"10.3389\/fimmu.2025.1575770","article-title":"Epithelial barrier hypothesis in the context of nutrition, microbial dysbiosis, and immune dysregulation in metabolic dysfunction-associated steatotic liver","volume":"16","author":"Cebi","year":"2025","journal-title":"Front. Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ebiom.2025.106037","article-title":"Periodontitis exacerbates metabolic dysfunction-associated steatotic liver disease via the gut microbiota-derived tryptophan metabolism-AHR axis in obesity","volume":"122","author":"Chen","year":"","journal-title":"EBioMedicine"},{"key":"B14","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12964-025-02299-5","article-title":"Common mechanisms of gut microbe-based strategies for the treatment of intestine-related diseases: based on multi-target interactions with the intestinal barrier","volume":"23","author":"Chen","year":"","journal-title":"Cell Commun. Signal."},{"key":"B15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.5009\/gnl240539","article-title":"Gut-liver axis: the role of intestinal microbiota and their metabolites in the progression of metabolic dysfunction-associated steatotic liver disease","volume":"19","author":"Cui","year":"2025","journal-title":"Gut Liver"},{"key":"B16","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3390\/antibiotics14040371","article-title":"The impact of antibiotic therapy on intestinal microbiota: dysbiosis, antibiotic resistance, and restoration strategies","volume":"14","author":"Cusumano","year":"2025","journal-title":"Antibiotics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.3390\/ijms24043074","article-title":"Antibiotic-therapy-induced gut dysbiosis affecting gut microbiota\u2014brain axis and cognition: restoration by intake of probiotics and synbiotics","volume":"24","author":"Dahiya","year":"2023","journal-title":"Int. Journal Molecular Sciences"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e01148","DOI":"10.1128\/msystems.01148-24","article-title":"Multi-omics analyses of the gut microbiota and metabolites in children with metabolic dysfunction-associated steatotic liver disease","volume":"10","author":"Du","year":"2025","journal-title":"Msystems"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1618275","DOI":"10.3389\/fmed.2025.1618275","article-title":"Metabolic dysfunction-associated steatotic liver disease (masld): the interplay of gut microbiome, insulin resistance, and diabetes","volume":"12","author":"Dua","year":"2025","journal-title":"Front. Medicine"},{"key":"B20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13102-022-00513-2","article-title":"Physical activity induced alterations of gut microbiota in humans: a systematic review","volume":"14","author":"Dziewiecka","year":"2022","journal-title":"BMC Sports Sci. Med. Rehabilitation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","year":"2024","journal-title":"J. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1435030","DOI":"10.3389\/fmed.2025.1435030","article-title":"Targeting gut microbiota dysbiosis in inflammatory bowel disease: a systematic review of current evidence","volume":"12","author":"Farah","year":"2025","journal-title":"Front. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2304157","DOI":"10.1080\/19490976.2024.2304157","article-title":"Disruption of gut barrier integrity and host\u2013microbiome interactions underlie MASLD severity in patients with type-2 diabetes mellitus","volume":"16","author":"Forlano","year":"2024","journal-title":"Gut Microbes"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1093\/nutrit\/nuad027","article-title":"Effect of gut microbiota modulation on sleep: a systematic review and meta-analysis of clinical trials","volume":"81","author":"Gil-Hernandez","year":"2023","journal-title":"Nutr. Reviews"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2541035","DOI":"10.1080\/19490976.2025.2541035","article-title":"Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial","volume":"17","author":"Groenewegen","year":"2025","journal-title":"Gut Microbes"},{"key":"B26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/gutjnl-2024-332398","article-title":"Interplay between gut microbiome, host genetic and epigenetic modifications in MASLD and MASLD-related hepatocellular carcinoma","volume":"74","author":"Ha","year":"2025","journal-title":"Gut"},{"key":"B27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/HEP.0000000000000985","article-title":"Intestinal IL-33 promotes microbiota-derived trimethylamine N-oxide synthesis and drives metabolic dysfunction\u2013associated steatotic liver disease progression by exerting dual regulation on HIF-1\u03b1","volume":"82","author":"Hai","year":"2025","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/nu17010143","article-title":"Dietary influences on gut microbiota and their role in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"Hamamah","year":"2024","journal-title":"Nutrients"},{"key":"B29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.3390\/nu16213722","article-title":"Synergistic effects of fructose and food preservatives on metabolic dysfunction-associated steatotic liver disease (MASLD): from gut microbiome alterations to hepatic gene expression","volume":"16","author":"Hrncir","year":"2024","journal-title":"Nutrients"},{"key":"B31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3350\/cmh.2025.0718","article-title":"Pediatric metabolic dysfunction\u2013associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation","volume":"32","author":"Jiang","year":"2025","journal-title":"Clin. Mol. Hepatology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13099-025-00782-5","article-title":"Gut microbiota and host transcriptome interactions reveal diagnostic biomarkers in MASLD-associated hepatocellular carcinoma","volume":"17","author":"Jinato","year":"2025","journal-title":"Gut Pathog."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/s42255-025-01318-6","article-title":"Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease","volume":"7","author":"Kim","year":"2025","journal-title":"Nat. Metabolism"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2020068","DOI":"10.1080\/19490976.2021.2020068","article-title":"The association of weight loss with changes in the gut microbiota diversity, composition, and intestinal permeability: a systematic review and meta-analysis","volume":"14","author":"Koutoukidis","year":"2022","journal-title":"Gut Microbes"},{"key":"B35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat. Rev. Gastroenterology & Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e70037","DOI":"10.1111\/obr.70037","article-title":"Impacts of lifestyle and microbiota\u2010targeted interventions for overweight and obesity on the human Gut microbiome: a systematic review","volume":"27","author":"Lee","year":"2026","journal-title":"Obes. Rev."},{"key":"B37","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of MASLD pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Disease"},{"key":"B38","doi-asserted-by":"publisher","first-page":"20220910","DOI":"10.1515\/biol-2022-0910","article-title":"Gut microbiota and sleep: interaction mechanisms and therapeutic prospects","volume":"19","author":"Lin","year":"2024","journal-title":"Open Life Sci."},{"key":"B39","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12866-025-03849-0","article-title":"Full-length 16S rRNA sequencing reveals gut microbiome signatures predictive of masld in children with obesity","volume":"25","author":"Lin","year":"2025","journal-title":"BMC Microbiology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0310","DOI":"10.1097\/hc9.0000000000000310","article-title":"Gut microbiota and metabolic biomarkers in metabolic dysfunction\u2013associated steatotic liver disease","volume":"8","author":"Long","year":"2024","journal-title":"Hepatol. Communications"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1016\/j.cmet.2025.10.017","article-title":"Interindividual variability in gut microbiome mediates the efficacy of resistant starch on MASLD","volume":"37","author":"Long","year":"2025","journal-title":"Cell Metab."},{"key":"B42","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.chom.2025.04.020","article-title":"Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects","volume":"33","author":"Luo","year":"2025","journal-title":"Cell Host & Microbe"},{"key":"B43","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13099-026-00826-4","article-title":"Microbiome\/transforming growth factor-\u03b2 axis as a diagnostic and therapeutic target for MASLD in Egyptian patients","volume":"18","author":"Marawan","year":"2026","journal-title":"Gut Pathog."},{"key":"B44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12866-025-04549-5","article-title":"Bacterial metabolic signatures in MASLD predicted through gene-centric studies in stool metagenomes","volume":"26","author":"Medina-M\u00e9ndez","year":"2025","journal-title":"BMC Microbiology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.3390\/ijms252011259","article-title":"The gut microbiome advances precision medicine and diagnostics for inflammatory bowel diseases","volume":"25","author":"Mousa","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"102256","DOI":"10.1016\/j.smrv.2026.102256","article-title":"What is the nature of sleep and circadian rhythm health on gastrointestinal microbiota? A systematic review of studies in humans","volume":"86","author":"Olson","year":"2026","journal-title":"Sleep. Medicine Reviews"},{"key":"B47","doi-asserted-by":"publisher","first-page":"16122","DOI":"10.1038\/s41598-024-60768-2","article-title":"Gut microbiota-based machine-learning signature for the diagnosis of alcohol-associated and metabolic dysfunction-associated steatotic liver disease","volume":"14","author":"Park","year":"2024","journal-title":"Sci. Reports"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/nu17111906","article-title":"Dietary strategies to modulate gut microbiota in metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"17","author":"Perazza","year":"2025","journal-title":"Nutrients"},{"key":"B49","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1101\/2024.01.29.24301919","article-title":"Physical activity, sedentary behavior and microbiome: a systematic review and meta-analysis","volume":"27","author":"P\u00e9rez-Prieto","year":"2024","journal-title":"J. Science Medicine Sport"},{"key":"B50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3350\/cmh.2024.0359","article-title":"Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments","volume":"31","author":"Pirola","year":"2024","journal-title":"Clin. Mol. Hepatology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"100579","DOI":"10.37349\/edd.2025.100579","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): emerging insights into gut microbiota interactions and therapeutic perspectives","volume":"4","author":"Qian","year":"2025","journal-title":"Explor. Dig. Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J. Hepatology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1053\/j.gastro.2025.02.035","article-title":"Machine learning and artificial intelligence in the multi-omics approach to gut microbiota","volume":"169","author":"Rozera","year":"2025","journal-title":"Gastroenterology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Saeed","year":"2024","journal-title":"Clin. Molecular Hepatology"},{"key":"B55","doi-asserted-by":"publisher","first-page":"20503121241257486","DOI":"10.1177\/20503121241257486","article-title":"Fecal microbiota transplantation and next-generation therapies: a review on targeting dysbiosis in metabolic disorders and beyond","volume":"12","author":"Sahle","year":"2024","journal-title":"SAGE Open Medicine"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s13300-026-01851-x","article-title":"Gut microbiota and metabolic health: from dysbiosis to therapeutics","volume":"17","author":"Sasidharan Pillai","year":"2026","journal-title":"Diabetes Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/nu16121800","article-title":"Distinct gut microbial signature and host genetic variants in association with liver fibrosis severity in patients with MASLD","volume":"16","author":"Satthawiwat","year":"2024","journal-title":"Nutrients"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.3390\/antiox13111386","article-title":"Gut microbiota and metabolic dysfunction-associated steatotic liver disease","volume":"13","author":"Scarpellini","year":"2024","journal-title":"Antioxidants"},{"key":"B60","doi-asserted-by":"publisher","first-page":"e186423","DOI":"10.1172\/jci186423","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations","volume":"135","author":"Schnabl","year":"2025","journal-title":"J. Clinical Investigation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"B62","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/antiox14010056","article-title":"Gut microbiota at the crossroad of hepatic oxidative stress and MASLD","volume":"14","author":"Termite","year":"2025","journal-title":"Antioxidants"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.3390\/nu16213663","article-title":"Physical exercise and the gut microbiome: a bidirectional relationship influencing health and performance","volume":"16","author":"Varghese","year":"2024","journal-title":"Nutrients"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1586678","DOI":"10.3389\/fmicb.2025.1586678","article-title":"Lactobacillus rhamnosus GG attenuates MASLD\/MASH progression by modulating gut microbiota and metabolic pathways","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Microbiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"759306","DOI":"10.3389\/fcimb.2022.759306","article-title":"Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial","volume":"12","author":"Xue","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1597995","DOI":"10.3389\/fmicb.2025.1597995","article-title":"Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota","volume":"16","author":"Yang","year":"2025","journal-title":"Front. Microbiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2024","journal-title":"Clin. Molecular Hepatology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1568672","DOI":"10.3389\/fmicb.2025.1568672","article-title":"Enterotype-stratified gut microbial signatures in MASLD and cirrhosis based on integrated microbiome data","volume":"16","author":"Yuan","year":"2025","journal-title":"Front. Microbiol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"4387","DOI":"10.3390\/ijms25084387","article-title":"Alteration of gut microbiota composition in the progression of liver damage in patients with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"25","author":"Zazueta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1549160","DOI":"10.3389\/fmicb.2025.1549160","article-title":"The human gut microbiota is associated with host lifestyle: a comprehensive narrative review","volume":"16","author":"Zeng","year":"2025","journal-title":"Front. Microbiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0484","DOI":"10.1097\/hc9.0000000000000484","article-title":"Gut microbial metabolites in MASLD: implications of mitochondrial dysfunction in the pathogenesis and treatment","volume":"8","author":"Zhang","year":"2024","journal-title":"Hepatol. Communications"},{"key":"B72","doi-asserted-by":"publisher","first-page":"100018","DOI":"10.1016\/j.pharmr.2024.100018","article-title":"Pharmacological treatment for metabolic dysfunction\u2013associated steatotic liver disease and related disorders: current and emerging therapeutic options","volume":"77","author":"Zhang","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"B73","doi-asserted-by":"publisher","first-page":"1740322","DOI":"10.3389\/fcimb.2025.1740322","article-title":"Gut microbiota modulation in gastrointestinal disorders: current evidence and therapeutic perspectives","volume":"15","author":"Zhang","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1007\/s12602-025-10593-4","article-title":"Probiotics mixture, prohep: a potential adjuvant for low-dose sorafenib in Metabolic dysfunction\u2013associated steatotic liver disease\u2013associated hepatocellular carcinoma suppression through modulating Gut Microbiota","volume":"18","author":"Zhang","year":"2026","journal-title":"Probiotics Antimicrob. Proteins"},{"key":"B75","doi-asserted-by":"publisher","first-page":"106203","DOI":"10.1016\/j.bbi.2025.106203","article-title":"Circadian rhythms and gut microbiota Dysbiosis: emerging gut-brain axis pathways in insomnia pathophysiology and therapeutics","volume":"132","author":"Zhao","year":"2025","journal-title":"Brain, Behav. Immun."},{"key":"B76","doi-asserted-by":"publisher","first-page":"101777","DOI":"10.1016\/j.aohep.2025.101777","article-title":"From gut to liver: exploring the crosstalk between gut-liver axis and oxidative stress in metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Zhou","year":"2025","journal-title":"Ann. Hepatology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/microorganisms14020471","article-title":"The gut\u2013liver axis in MASLD: from host\u2013microbiome crosstalk to precision therapeutics","volume":"14","author":"Zhou","year":"2026","journal-title":"Microorganisms"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e71687","DOI":"10.1096\/fj.202503607rr","article-title":"The gut\u2010liver axis in metabolic dysfunction\u2010associated steatotic liver disease: from mechanistic insights to precision therapeutics","volume":"40","author":"Zhu","year":"2026","journal-title":"FASEB J."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2508951","DOI":"10.1080\/19490976.2025.2508951","article-title":"Meta-analysis of shotgun sequencing of gut microbiota in obese children with MASLD or MASH","volume":"17","author":"Z\u00f6ggeler","year":"2025","journal-title":"Gut Microbes"}],"container-title":["Frontiers in Systems Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsysb.2026.1937809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:34:27Z","timestamp":1790332467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fsysb.2026.1937809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":79,"alternative-id":["10.3389\/fsysb.2026.1937809"],"URL":"https:\/\/doi.org\/10.3389\/fsysb.2026.1937809","relation":{},"ISSN":["2674-0702"],"issn-type":[{"value":"2674-0702","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1937809"}}